Management of Device Detected AT and Impact of Device Treatment Algorithms on Atrial Fibrillation

N/A Terminated NCT04172883

Summary

The MANDATE-AF study was designed to address evidence needs in India for device-based management of AF using AT/AF (Atrial Tachycardia/Atrial fibrillation) diagnostic features and therapies such as Reactive Atrial anti tachycardia Pacing (rATP) within Medtronic Cardiac Implantable Electronic Devices (CIED)and its impact on the time to persistent AF and progression of AT/AF.

Incidence of 'Persistent AF' Over Time

up to 18 months · percentage probability

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomati — Insel Gruppe AG, University Hospital Bern
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
• Amplatzer Amulet China Post Market Study (PMS) — Abbott Medical Devices
• Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmia — Oxford University Hospitals NHS Trust
• Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation — Massachusetts General Hospital
• Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With N — Intermountain Health Care, Inc.

All trials